Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALC NASDAQ:CLYM NASDAQ:ELDN NASDAQ:NKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALCCalciMedica$2.70-1.1%$2.57$1.42▼$5.97$38.14M1.3337,284 shs9,187 shsCLYMClimb Bio$2.23-3.0%$1.61$1.05▼$8.79$155.86M-0.11878,948 shs288,883 shsELDNEledon Pharmaceuticals$2.59+0.8%$3.06$2.38▼$5.54$153.90M-0.15956,680 shs490,653 shsNKTXNkarta$2.12-3.6%$2.01$1.31▼$6.63$156.25M0.72534,375 shs345,977 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALCCalciMedica-1.10%-2.88%-26.63%+62.22%-35.71%CLYMClimb Bio-3.04%-6.30%+46.71%+84.30%+222,999,900.00%ELDNEledon Pharmaceuticals+0.78%-0.38%-18.04%-14.24%-9.12%NKTXNkarta-3.64%-10.55%-2.75%+20.80%-59.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALCCalciMedica3.4595 of 5 stars3.55.00.00.03.13.30.0CLYMClimb Bio3.3212 of 5 stars3.70.00.00.03.32.51.3ELDNEledon Pharmaceuticals1.7073 of 5 stars3.41.00.00.02.81.70.0NKTXNkarta2.0874 of 5 stars3.50.00.00.03.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALCCalciMedica 3.00Buy$16.00492.59% UpsideCLYMClimb Bio 3.33Buy$9.00303.59% UpsideELDNEledon Pharmaceuticals 2.75Moderate Buy$10.00286.10% UpsideNKTXNkarta 3.00Buy$13.60541.51% UpsideCurrent Analyst Ratings BreakdownLatest CALC, CLYM, ELDN, and NKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025ELDNEledon PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025CLYMClimb BioBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/15/2025CLYMClimb BioRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$9.008/14/2025NKTXNkartaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.008/13/2025NKTXNkartaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.007/25/2025ELDNEledon PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/18/2025ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$9.006/10/2025NKTXNkartaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $14.006/6/2025CLYMClimb BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$10.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALCCalciMedicaN/AN/AN/AN/A$0.44 per shareN/ACLYMClimb BioN/AN/AN/AN/A$2.74 per shareN/AELDNEledon PharmaceuticalsN/AN/AN/AN/A$0.84 per shareN/ANKTXNkartaN/AN/AN/AN/A$5.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALCCalciMedica-$13.70M-$1.60N/AN/AN/AN/A-206.51%-103.81%11/12/2025 (Estimated)CLYMClimb Bio-$73.90M-$0.70N/AN/AN/AN/A-23.10%-22.47%11/11/2025 (Estimated)ELDNEledon Pharmaceuticals-$36.18M-$1.17N/AN/AN/AN/A-92.51%-38.31%11/11/2025 (Estimated)NKTXNkarta-$108.79M-$1.48N/AN/AN/AN/A-27.74%-22.38%11/6/2025 (Estimated)Latest CALC, CLYM, ELDN, and NKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ELDNEledon Pharmaceuticals-$0.23-$0.13+$0.10-$0.13N/AN/A8/12/2025Q2 2025CALCCalciMedica-$0.40-$0.40N/A-$0.40N/AN/A8/12/2025Q2 2025CLYMClimb Bio-$0.19-$0.13+$0.06-$0.13N/AN/A8/12/2025Q2 2025NKTXNkarta-$0.37-$0.31+$0.06-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALCCalciMedicaN/AN/AN/AN/AN/ACLYMClimb BioN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALCCalciMedica1.395.455.45CLYMClimb BioN/A14.0814.08ELDNEledon PharmaceuticalsN/A8.128.12NKTXNkartaN/A15.6715.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALCCalciMedicaN/ACLYMClimb Bio69.76%ELDNEledon Pharmaceuticals56.77%NKTXNkarta80.54%Insider OwnershipCompanyInsider OwnershipCALCCalciMedica41.55%CLYMClimb Bio0.80%ELDNEledon Pharmaceuticals12.30%NKTXNkarta8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALCCalciMedica3013.97 million8.17 millionNo DataCLYMClimb Bio967.76 million67.22 millionN/AELDNEledon Pharmaceuticals1059.88 million52.52 millionOptionableNKTXNkarta14071.03 million65.06 millionOptionableCALC, CLYM, ELDN, and NKTX HeadlinesRecent News About These CompaniesNkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of "Buy" by BrokeragesAugust 26, 2025 | marketbeat.comNkarta (NASDAQ:NKTX) Stock Rating Upgraded by Wall Street ZenAugust 19, 2025 | americanbankingnews.comEquities Analysts Issue Forecasts for Nkarta Q3 EarningsAugust 17, 2025 | marketbeat.comEquities Analysts Set Expectations for Nkarta Q3 EarningsAugust 17, 2025 | marketbeat.comWall Street Zen Upgrades Nkarta (NASDAQ:NKTX) to "Hold"August 17, 2025 | marketbeat.comNkarta (NASDAQ:NKTX) Given New $12.00 Price Target at Stifel NicolausAugust 16, 2025 | marketbeat.comNkarta (NASDAQ:NKTX) Receives Buy Rating from Needham & Company LLCAugust 15, 2025 | marketbeat.comNkarta price target lowered to $12 from $14 at StifelAugust 15, 2025 | msn.comNkarta (NASDAQ:NKTX) Announces Earnings Results, Beats Estimates By $0.06 EPSAugust 14, 2025 | marketbeat.comNkarta, Inc.: Nkarta Reports Second Quarter 2025 Financial Results and Corporate HighlightsAugust 13, 2025 | finanznachrichten.deNkarta, Inc. Reports Q2 2025 Financial ResultsAugust 12, 2025 | tipranks.comNkarta Reports Second Quarter 2025 Financial Results and Corporate HighlightsAugust 12, 2025 | globenewswire.comNkarta (NKTX) Expected to Announce Earnings on TuesdayAugust 6, 2025 | marketbeat.comMonaco Asset Management SAM Invests $1.50 Million in Nkarta, Inc. (NASDAQ:NKTX)July 31, 2025 | marketbeat.comNkarta, Inc. (NASDAQ:NKTX) Receives Consensus Recommendation of "Buy" from AnalystsJuly 30, 2025 | marketbeat.comNkarta to Participate in the H.C. Wainwright "HCW@Home" SeriesJuly 23, 2025 | tmcnet.comNkarta to Participate in the H.C. Wainwright “HCW@Home” SeriesJuly 23, 2025 | globenewswire.comNkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025July 22, 2025 | seekingalpha.comWill Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely?June 27, 2025 | uk.finance.yahoo.comNkarta, Inc. (NKTX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comNkarta CMO David Shook Steps Down, Shawn Rose To SucceedJune 7, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksBy Thomas Hughes | August 19, 2025Navitas Stock's Dip: A Calculated Risk or a Clear Buy Signal?By Jeffrey Neal Johnson | August 7, 2025CALC, CLYM, ELDN, and NKTX Company DescriptionsCalciMedica NASDAQ:CALC$2.70 -0.03 (-1.10%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.73 +0.03 (+1.11%) As of 08/29/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Climb Bio NASDAQ:CLYM$2.23 -0.07 (-3.04%) As of 08/29/2025 04:00 PM EasternClimb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.Eledon Pharmaceuticals NASDAQ:ELDN$2.59 +0.02 (+0.78%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.60 +0.01 (+0.39%) As of 08/29/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Nkarta NASDAQ:NKTX$2.12 -0.08 (-3.64%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.19 +0.07 (+3.30%) As of 08/29/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
